# US 2021/0171480 A1 · Benzothia(di)azepine compounds and their use as bile acid modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171480 A1
- Document ID: US20210171480A1
- Status: Published application
- Kind: A1
- Application number: 17/144,568
- Filed: 2021-01-08
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Albireo AB
- Applicants: Albireo AB
- Inventors: Per-Göran Gillberg; Ingemar Starke; Santosh S. Kulkarni
- Web page: https://patentgrep.com/patent/US20210171480A1

## CPC

- C07D 281/10: condensed with one six-membered ring
- C07D 285/36: Seven-membered rings
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

## Claims

### Claim 1

A compound of formula (I)
wherein
M is selected from —CH2— and —NR6—;
R1 is C1-4 alkyl;
R2 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, cyano, nitro, amino, N—(C1-4 alkyl)amino, N,N-di(C1-4 alkyl)-amino, N-(aryl-C1-4 alkyl)amino, C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, N—(C1-4 alkyl)aminocarbonyl, N,N-di(C1-4 alkyl)aminocarbonyl, C1-4 alkyloxycarbonylamino, C3-6 cycloalkyloxycarbonylamino, C1-4 alkylsulfonamido and C3-6 cycloalkylsulfonamido;
n is an integer 1, 2 or 3;
R3 is selected from the group consisting of hydrogen, halogen, cyano, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, C3-6 cycloalkyloxy, C1-4 alkylthio, C3-6 cycloalkylthio, amino, N—(C1-4 alkyl)amino and N,N-di(C1-4 alkyl)amino;
One of R4 and R5 is carboxyl, and the other of R4 and R5 is selected from the group consisting of hydrogen, fluoro, C1-4 alkyl and C1-4 haloalkyl;
R6 is selected from the group consisting of hydrogen and C1-4 alkyl; and
R7 is selected from the group consisting of hydrogen and C1-4 alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is n-butyl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R1 is n-propyl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R2 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino, isopropylcarbonylamino, tert-butylcarbonylamino, tert-butylaminocarbonyl, tert-butoxycarbonylamino, methylsulfonamido and cyclopropylsulfonamido.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino and dimethylamino.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R4 is hydrogen or fluoro.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R5 is carboxyl.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R6 is hydrogen.

### Claim 9 (depends on 1)

A compound according to claim 1, selected from the group consisting of:
(Z)-3-((3-butyl-3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid;
(R)-(Z)-3-((3-butyl-3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid;
(S)-(Z)-3-((3-butyl-3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid;
(E)-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid;
(S)-(E)-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid;
(R)-(E)-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid;
(Z)-2-fluoro-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid;
(R)-(Z)-2-fluoro-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid;
(S)-(Z)-2-fluoro-3-((3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-3-propyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acrylic acid; and
(Z)-3-((3-ethyl-3-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-fluoroacrylic acid;
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim at position 11

-21. (canceled)
